Mark S. Cohen
Président chez Tarus Therapeutics, Inc.
Profil
Mark S.
Cohen is the founder of Pearl Cohen Zedek Latzer LLP, which was founded in 1999.
He served as the Chairman of the Life Science Group & Senior Partner from 2012 to 2013.
Currently, he is the Chairman of Tarus Therapeutics, Inc. since 2021 and Chairman of the Life Sciences Practice Group.
In the past, he served as the Executive Chairman of Celsus Therapeutics Plc from 2013 to 2015 and Vice Chairman of Akari Therapeutics Plc.
He also served as a Director of Catalent MSTC, Inc. Mr. Cohen received his undergraduate degree from Rutgers State University of New Jersey and his graduate degree from New York University.
He also received a graduate degree from the University of Baltimore School of Law.
Postes actifs de Mark S. Cohen
| Sociétés | Poste | Début |
|---|---|---|
Tarus Therapeutics, Inc.
 Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Président | 01/01/2021 |
| Life Sciences Practice Group | Président | - |
Anciens postes connus de Mark S. Cohen
| Sociétés | Poste | Fin |
|---|---|---|
| AKARI THERAPEUTICS, PLC | Directeur/Membre du Conseil | 14/10/2016 |
| Pearl Cohen Zedek Latzer LLP | Fondateur | 26/07/2013 |
Catalent MSTC, Inc.
 Catalent MSTC, Inc. Medical SpecialtiesHealth Technology Catalent MSTC, Inc. provides full service contract development and manufacturing services (CDMO) for cell therapy companies. It offers process and assay development, quality management, and cGMP cell therapy manufacturing services. The company was incorporated on December 27, 2017 and is headquartered in Dover, DE. | Directeur/Membre du Conseil | - |
Celsus Therapeutics Plc
 Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Président | - |
Formation de Mark S. Cohen
| Rutgers State University of New Jersey | Undergraduate Degree |
| New York University | Graduate Degree |
| University of Baltimore School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AKARI THERAPEUTICS, PLC | Health Technology |
| Entreprise privées | 5 |
|---|---|
Celsus Therapeutics Plc
Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
| Pearl Cohen Zedek Latzer LLP | Commercial Services |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Health Technology |
Catalent MSTC, Inc.
Catalent MSTC, Inc. Medical SpecialtiesHealth Technology Catalent MSTC, Inc. provides full service contract development and manufacturing services (CDMO) for cell therapy companies. It offers process and assay development, quality management, and cGMP cell therapy manufacturing services. The company was incorporated on December 27, 2017 and is headquartered in Dover, DE. | Health Technology |
| Life Sciences Practice Group |
